thecardiologyadvisor.com23 小时
Nasal Spray Formulation of Bumetanide Under FDA Review
The FDA has accepted for review the NDA for bumetanide nasal spray for edema associated with CHF, as well as hepatic and renal disease.
WebMD7 天
What to Know About the New Nasal Spray for Tough Depression
CIII allows people who have tried at least two oral antidepressants to use the spray on its own – without the need for more ...
Padagis Naloxone Now the Lowest Priced Opioid Overdose Treatment Available on Amazon
Padagis®, a leading generic manufacturer, announced today it is lowering the price of its over-the-counter (OTC) 4 mg ...
Medical News Today8 天
FDA-approved nasal spray for severe depression can lead to remission
The Food and Drug Administration (FDA) recently approved the nasal spray Spravato for the treatment of major depression in ...
FDA approves first-of-its-kind nasal spray for severe depression
Johnson & Johnson has announced the FDA’s approval of a first-of-its-kind, esketamine nasal spray called Spravato for the ...
Yahoo Finance8 天
Corstasis Therapeutics Inc. Announces FDA Acceptance of New Drug Application for Bumetanide ...
(www.corstasis.com), a clinical-stage MedTech pharmaceutical company developing innovative, practical therapies for fluid ...
U.S. News & World Report13 天
FDA Approves Spravato Nasal Spray for Treatment-Resistant Depression
WEDNESDAY, Jan. 22, 2025 (HealthDay News) -- The U.S. Food and Drug Administration has approved Spravato (esketamine) CIII nasal spray for adults living with major depressive disorder who have had an ...